Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - mupirocin calcium, quantity: 20.7683 mg/g - cream - excipient ingredients: cetyl alcohol; benzyl alcohol; purified water; cetomacrogol 1000; stearyl alcohol; liquid paraffin; xanthan gum; phenoxyethanol - bactroban (mupirocin) cream is indicated for the topical treatment of secondarily infected traumatic skin lesions such as small lacerations, sutured wounds or abrasions.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

haleon uk ltd - phenylephrine hydrochloride; guaifenesin; paracetamol - powder - 12.2mg ; 200mg ; 1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - diphtheria toxoid, quantity: 2 iu; pertussis toxoid, quantity: 8 microgram; tetanus toxoid, quantity: 20 iu; pertactin, quantity: 2.5 microgram; pertussis filamentous haemagglutinin, quantity: 8 microgram; poliovirus, quantity: 32 agu - injection, suspension - excipient ingredients: polysorbate 80; aluminium hydroxide hydrate; sodium chloride; neomycin sulfate; water for injections; aluminium phosphate; polymyxin b sulfate; glucose monohydrate; ascorbic acid; calcium chloride dihydrate; ferric nitrate nonahydrate; potassium chloride; magnesium sulfate heptahydrate; monobasic potassium phosphate; dibasic sodium phosphate; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine phosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride monohydrate; sodium hypoxanthine; ribose; sodium acetate; thymine; uracil; sodium xanthine; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; isoleucine; hydroxyproline; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; dl-threonine; dl-tryptophan; tyrosine disodium; dl-valine; biotin; ergocalciferol; calcium pantothenate; choline chloride; folic acid; inosit - boostrix-ipv is indicated for booster vaccination against diphtheria, tetanus, pertussis and polio of individuals from the age of four years onwards.,boostrix-ipv is also indicated for passive protection against pertussis in early infancy following maternal immunisation during pregnancy (see section 4.2 dose and method of administration, section 4.6 fertility, pregnancy and lactation and 5.1 pharmacodynamic properties).,the nhmrc currently recommends only 4 doses of polio vaccines in childhood, and that polio boosters for adults are not necessary unless they are at special risk, such as:,? travellers to areas or countries where poliomyelitis is epidemic or endemic;,? health care workers in possible contact with poliomyelitis cases.,for those exposed to continuing risk of infection a single booster dose is desirable every 10 years.,the nhmrc currently recommends boosting against diphtheria, tetanus and pertussis using an adolescent/adult formulation dtpa at 15 to 17 years of age. before the eighth birthday, dt

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 0.48 mg/ml (equivalent: salbutamol, qty 0.4 mg/ml) - oral liquid - excipient ingredients: sodium benzoate; hypromellose; citric acid monohydrate; sodium chloride; purified water; sodium citrate dihydrate; saccharin sodium; flavour - indications as at 14 february 2005: ventolin is indicated for the prevention and relief of bronchospasm in bronchial asthma of all types and for the alleviation of any reversible airways obstruction associated with conditions such as chronic bronchitis or emphysema.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 400 microgram - nasal drops - excipient ingredients: polysorbate 20; sorbitan monolaurate; monobasic sodium phosphate; dibasic sodium phosphate; sodium chloride; water for injections - indications: for the treatment of mild to moderate nasal polyps and associated symptoms of nasal obstruction in adults and adolescents over 16 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - rosiglitazone maleate -

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - salbutamol sulfate, quantity: 120.5 microgram/actuation (equivalent: salbutamol, qty 100 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - other conditions: do not puncture or incinerate even when empty as canister may explode. indications: for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise-induced asthma and other stimuli known to induce bronchospasm.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - aciclovir -